St-Georges Eco-Mining Subsidiary ZeU Crypto Signs Definitive Agreement with Tiande
Momentum Public Relations
Press Release: February 26 2018
St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF) (FSE: 85G1) announces that, further to its January 15 and February 8, 2018 press releases, its wholly owned subsidiary ZeU Crypto Networks Inc. has signed a definitive asset purchase agreement dated February 23, 2018 with Qingdao Tiande Technologies Limited and Beijing Tiande Technologies Limited w ith the intervention of Guiyang Tiande Technologies Limited to purchase substantially all the intellectual property of the Vendors.
The following are the material terms of the agreement:
- – ZeU will acquire the Vendor’s intellectual property (including without limitation, all intellectual property and patent applications directly or indirectly related to the Blockchain and smart contract technologies of the Vendors (the ” Blockchain Technology “), including without limitation, BigData, IoB, Sandbox) (the ” IP “)
- – the Vendors will complete: (i) the transfer and successful employment by ZeU of all key employees; (ii) the transfer and assignment of all the IP to ZeU; (iii) the obtaining of all regulatory approvals should they be required; and (iv) the obtaining of all required consents including all consents from clients and collaborators pursuant to the existing contracts of the Vendors (the ” Milestone Conditions “)
- – ZeU, the Vendors and key collaborators will enter into a license agreement and non-competition covenant which will provide, among other things, that ZeU shall irrevocably grant a perpetual , exclusive, transferable and sub-licensable license to the Vendors for use of the Blockchain Technology in China, Hong Kong and Taiwan
- – ZeU will have completed or caused to be completed prior to the Closing Date a debenture financing of not less than $10,000,000 and up to $30,000,000 (the ” Concurrent Financing “)
The purchase price for the Acquisition shall be up to 150,000,000 common shares of ZeU (each a ” Share ” and 150,000,000 Share purchase warrants (each a ” Warrant “) to the Vendors, satisfied by (i) the delivery of a total of 65,000,000 Shares and 75,000,000 Warrants on the closing date of the Acquisition (the ” Closing Date “), (ii) to the extent and only if all of the Milestone Conditions (as defined hereinabove) are satisfied, the delivery of an additional 75,000,000 Shares, within 3 Business Days following the satisfaction of the Milestone Conditions or the Closing Date (whichever is later) and (iii) to the extent and only if twenty (20) new patents pertaining to the Blockchain Technology are issued (the ” Patent Condition “), the delivery of an additional 75,000,000 Shares, within 3 Business Days following the satisfaction of the Patent Condition .
Each Warrant will be exercisable at a price equal to the conversion price pursuant to the Concurrent Financing for a period of three (3) years following the date ZeU completes a transaction pursuant to which its Shares will either be listed on a recognized stock exchange in North America, or will be exchanged for common shares of a reporting issuer listed on a recognized stock exchange in North America.
The agreement was negotiated at arm’s length, and contains customary representations, warranties and closing conditions.
On closing of the Acquisition, Dr. Wei Tek Tsai is to join ZeU’s management as Chief Technology Officer.
The Acquisition remains subject to requisite regulatory approval and satisfaction of closing conditions contained in the agreement.
The Acquisition remains subject to a number of conditions as set forth in the agreement, including (without limitation), the completion of the Concurrent Financing (as defined hereinabove), the receipt of all requisite regulatory approvals and satisfaction of closing conditions contained in the agreement.
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS, PRESIDENT & CEO
About St-Georges
St-Georges is developing new technologies to solve the some of the most common environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange under the symbol 85G1.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in St-Georges Eco-Mining, Uncategorized
Tetra Bio-Pharma names Aphria CFO as Chairman of Audit Committee
Momentum Public Relations
Press Release: February 26, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), announced changes to its Board of Directors (the “Board”) today, including the appointment of Aphria Inc.’s Chief Financial Officer (CFO), Mr. Carl Merton, as Chair of Tetra’s Audit Committee.
In addition to his extensive financial background, Mr. Merton is a Chartered Accountant and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.
Mr. Merton has served on the Tetra Board since 2016 and brings over 20 years of financial and business experience to the Audit Committee. He replaces Mr. Robert Brouillette, whose resignation was accepted immediately upon the Board becoming aware that a decision had been rendered by a professional regulatory organization against Mr. Brouillette in relation to professional activities unrelated to his responsibilities as a director of Tetra.
Mr. André Rancourt, Tetra’s Chair, was also named to the Audit Committee. Mr. Rancourt also acts as a consultant on several commercial strategy committees including FIA and IRZC. He has significant practical experience that provided him with expertise in many fields, including human and animal natural health products. Over the last ten years, he worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds.
“These appointments further strengthen our corporate governance practices,” said Tetra CEO Bernard Fortier. “Both Mr. Merton and Mr. Rancourt have stellar reputations in the capital market and will continue to provide our management team and our entire Board with support and guidance as we embark on the next stage of our growth.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Andre Rancourt
Executive Chairman
andre.r@tetrabiopharma.com
(438) 899-7575
- Published in Tetra Bio Pharma, Uncategorized
Arctic Star Mobilizes Drill, Timantti Project Finland
Momentum Public Relations
Press Release: February 9 2018
Arctic Star Exploration Corp (TSXV: ADD) (OTCQB: ASDZF) (FSE: 82A1) (WKN: A2DFY5) (“Arctic” or the “Company”) is pleased to announce that a diamond drill rig will arrive at site on its 100% owned Timantti Diamond Project in Finland (the “Project”) on February 12, 2018 and will commence drilling shortly after. The drill will test newly identified kimberlite targets.
Since early December geophysical crews have been active in the field conducting magnetic, electromagnetic (MaxMin) and gravity surveys over much of the 243 Ha Exploration Reservation area. In mid-January the Company deployed an excavator to collect till samples to further support geophysics results. The basil till covering potential kimberlites on the Project is only one or two metres thick.
The purpose of conducting ground magnetic, electromagnetic and gravity surveys is to search for new kimberlitic targets and to discriminate these from non-kimberlite geophysical responses. A total of 41-line kilometres of electromagnetic (MaxMin) is planned, of which approximately 50% has been completed. Approximately 35 kilometres of gravity survey is also planned, of which 55% has been completed. There are also 61-line kilometres of ground magnetics planned of which 35% is now complete.
The Wolf kimberlites are moderate magnetic highs in a fairly magnetically noisy background with iron formations and mafic volcanics producing similar or more intense responses. At this stage, there are over twenty magnetic anomalies that may represent kimberlite targets in the general Wolf area, the gravity and MaxMin survey will help further prioritize these targets prior to drilling. The Wolf kimberlites for example also have an electromagnetic response.
The excavator is sampling the basal till, “down-ice” of the more promising geophysical anomalies. Four targets have been tested to date, and the samples have been sent to laboratory to extract indicator minerals. The drill will be directed to any of these that report diamond indicator minerals.
The drill will also be utilized to further delineate the Wolf kimberlites and return a larger caustic fusion micro-diamond sample to further determine the size and grade for a decision to bulk sample these diamondiferous kimberlites.
Buddy Doyle VP of Exploration commented, “By rapidly deploying these different exploration tools to our exploration permit, we expect to obtain multiple layers of evidence of new kimberlites that can be drill tested. We know there are more kimberlites in this area by the expression of diamond favorable indicator minerals in the region, which the Wolf kimberlites cannot explain. The company also will produce a steady stream of caustic diamond fusion results from drilling the Wolf kimberlites, which, so far have produced encouraging micro-diamond counts. The next six weeks will be an exciting time for the company.”
The Qualified Person for this news release is Roy Spencer, Fellow AUSIMM, a Geologist of over thirty years’ experience in diamonds.
ABOUT ARCTIC STAR: The Company owns 100% of the recently acquired Timantti Diamond Project including a 243 Ha Exploration Permit and a 95,700 Ha Exploration Reservation near the township of Kuusamo, in Finland. The project is located approximately 450km SW of the operating Grib Diamond Mine in Russia. Arctic is commencing its exploration in Finland on the Timantti Project, where two diamondiferous kimberlites may represent the first finds in a large kimberlite field. The Company also controls diamond exploration properties in Nunavut (Stein), the NWT (Diagras and Redemption) and a rare metals project in BC (Cap).
Arctic Star has a highly experienced diamond exploration team previously responsible for several world class diamond discoveries.
ON BEHALF OF THE BOARD OF DIRECTORS OF ARCTIC STAR EXPLORATION CORP.
“Scott Eldridge”
Scott Eldridge, President & CEO
+1 (604) 722-5381
scott@arcticstar.ca
Patrick Power, Executive Chairman
+1 (604) 218-8772
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements: Certain statements in this press release are forward-looking statements within the meaning of applicable securities laws. Forward-looking statements in this press release include that the Timantti Project transaction is a pre-eminent opportunity.
- Published in Uncategorized
St-Georges Eco-Mining Announces Amendment to the Letter of Intent Between its Subsidary ZEU CRYPTO NETWORKS INC. and TIANDE
Momentum Public Relations
Press Release: February 7 2018
– St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF)
(FSE: 85G1) announced today that its previously announced letter of intent dated January 12,
2018 relating to an asset acquisition between SX’s subsidiary, ZeU Crypto Networks Inc. and
Qingdao Tiande Blockchain Information Technology Co. Ltd. has been amended. The general
terms of the LOI, which referred to Qingdao Tiande Technologies Limited instead of Qingdao, were
previously announced by press release dated January 14, 2018.
ZeU, Qingdao and Beijing Tiande Technologies Limited. (“Beijing” and collectively with
Qingdao, “Tiande”) entered into the amendment to the LOI (the “Amendment”), which has
extended the date by which the parties will conclude the execution of a definitive agreement on
or around February 19, 2018 or such later date as may be mutually agreed upon by the
parties. The proposed acquisition is subject to a number of terms and conditions, including but
not limited to, the completion of a concurrent financing not less than $10,000,000 and up to
$30,000,000 that can be done in tranches and the receipt of all necessary regulatory, corporate
and third party approvals.
The Amendment also revised the consideration structure, such that the proposed Acquisition will
now be settled through the issuance of 75,000,000 common shares of ZeU (each a “Share”) and
75,000,000 Share purchase warrants (each a “Warrant”) on Closing and an additional
75,000,000 Shares after the filing for registration of the 20th patent derived from the intellectual
property and patent application acquired from Tiande. Each Warrant will be exercisable at a
price of CND$1.00 for a period of three (3) years following the date ZeU completes a transaction
pursuant to which its Shares will either be listed on a recognized stock exchange in North
America, or will be exchanged for common shares of a reporting issuer listed on a recognized
stock exchange in North America.
Frank Dumas, President & CEO of St-Georges and of ZeU Crypto Networks commented: “The
Acquisition required an extensive due diligence effort and has its own particular challenges. We
are happy with the current progress and we can now see the finish line ahead of us. Some
elements that are ‘sensitive’ to third party sovereign entities increased the expected workload.
The current proposal should allow Tiande to operate in China as an exclusive partner to ZeU,
giving ZeU the exclusive ownership and right to develop and commercialize the technologies
outside of China and would also call for the establishment of a “Canadian Intellectual Property
(IP) Container” and a “Chinese Intellectual Property (IP) Container” allowing for a “Chinese
Source Code” to be exclusively used in China without any possibility for North American
oversight.”
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS, PRESIDENT & CEO
About St-Georges
St-Georges is developing new technologies to solve the some of the most common
environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active
mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial
minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the
Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the
symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange
under the symbol 85G1.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility
for the adequacy or the accuracy of the contents of this release.
Compliance and medias contact: 514.295.9878
- Published in St-Georges Eco-Mining, Uncategorized
AREV Nutrition Sciences Inc. Announces Attendance At Capital Events Bahamas, Conversion Of The Convertible Debenture And Issuance Of Stock Options
Momentum Public Relations
Press Release: January 9, 2018
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – ARV ), is pleased to announce that that they will be attending the AlphaNorth Capital Conference at the Atlantis Paradise Island Resort in the Bahamas from January 12 – 14, 2018, hosted by Capital Event Conferences. The conference introduces growth-stage companies (Resource, Technology, Biotech, Special Situations) to active top-level capital finance individuals through a day of scheduled one-on-one meetings.
The Company is also pleased to announce that Chiron Capital Inc., a company directly controlled by Mike Withrow, has converted the second of two convertible debentures into units of the Company, each unit consisting of a common share of the Company and a common share warrant of the Company. The total principal amount of the convertible debentures exercised is $300,000. The convertible debentures has been converted into units of the Company at a conversion price of $0.05 per unit with a term ending September 16, 2018.
The conversion of this Convertible Debenture retires long term debt of the C ompany.
After converting the debenture, Chiron Capital Inc., has exercised 2,000,000 warrants at a price of $0.05 per common share for a total cost of $100,000.
If all of Mike Withrow’s convertible securities were converted into common shares of the Company Mike Withrow would control 18,112,000 (42%) of a total of 43,342,800 fully diluted common shares of the Company.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2018 TheNewswire – All rights reserved.
- Published in AREV Nutrition Sciences, Marijuana, Uncategorized
Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC
Momentum Public Relations
Press Release: December 13, 2017
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering Research Council of Canada (NSERC) grant in its collaborative project with Dr Stan Kubow at McGill university.
Constance Therapeutics has developed whole plant cannabis extracts that have shown significant clinical promise in the treatment of various forms of cancer and improved patient survival as well. In collaboration, Tetra and Constance Therapeutics now aim to define the therapeutic mechanism and demonstrate efficacy of these cannabis extracts in the treatment of human cancers. In accordance with Tetra’s provisional patent announced on May 17th, 2017, the collaboration will focus on treating various forms of cancer driven by inappropriate Hedgehog signaling, including multiple forms of brain, blood, skin and bone cancers.
Constance Finley, Founder and CEO of Constance Therapeutics, Inc. said, “over the years, research has demonstrated that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”
“We are very excited to achieve this co-development program with Constance Therapeutics” added Bernard Fortier, CEO of Tetra. “Their initial research is very promising and we are hopeful that together we can provide novel treatments for multiple forms of aggressive cancer to patients with limited therapeutic options. ”
In addition, Tetra is pleased to announce that the company has been awarded an additional Engage Plus grant from the National Sciences and Engineering Research Council of Canada (NSERC) to continue the collaborative project with Dr. Stan Kubow of McGill University. The goal of the basic research project is to explore and develop patentable cannabis-derived retail supplements and drug products in partnership with McGill University, and the grant awarded by NSERC will bolster Tetra Bio-Pharma’s investment with matching funds up to a maximum of $12,500.
“We are excited and honored to have the continued support of NSERC on this innovative project with McGill. Through the use of Dr. Kubow’s expertise and access to the advanced facility at McGill University, we aim to develop novel natural health supplements and drug products to be commercialized by Tetra,” commented Dr. Guy Chamberland, Chief Scientific Officer or Tetra Bio-Pharma.
Together, the co-development project focused on treating Hh-driven disease and the continuation of the McGill collaboration aiming to develop new cannabis-based products diversifies and strengthens Tetra’s pre-clinical program, thus ensuring the continuity of the product pipe-line in the future.
Lassen U, Mau-Sørensen M, Poulsen HS Orphan drugs in glioblastoma multiforme: a review Orphan Drugs: Research and Reviews 2014:4; 83-91
About Constance Therapeutics:
Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals to offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420.
More information at: www.constancetherapeutics.com
About Dr. Stan Kubow:
Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
- Published in Uncategorized
Crystal Lake’s two placements oversubscribed
Momentum Public Relations
Press Release: November 27, 2017
Crystal Lake Mining Corp. (CLM:tsxv) has received subscriptions for two million units totalling $400,000 pursuant to the non-brokered, non-flow-through private placement announced on Nov. 6, 2017. Each unit consists of one common share issued at 20 cents per share, and one common share purchase warrant. One warrant may be exercised by the holder to purchase one additional common share at a price of 25 cents for 18 months from closing.
In addition, the company has received subscriptions for two million flow-through units totalling $500,000 pursuant to the flow-through private placement announced on Oct. 26, 2017. Each flow-through unit consists of one flow-through common share issued at 25 cents per share, and one-half of one non-flow-through common share purchase warrant. One warrant may be exercised by the holder to purchase an additional non-flow-through common share at a price of 30 cents for 18 months from closing.
The proceeds of this private placement will be used to advance exploration activities at the company’s Emo, Ont., properties and for general working capital.
Both the flow-through and non-flow-through private placements were oversubscribed.
Finders’ fees are payable to qualified recipients at the rates allowable by the TSX Venture Exchange. All securities issued are subject to a four-month hold period and closing remains subject to TSX-V approval.
About Crystal Lake Mining Corp.
Crystal Lake Mining is a mineral exploration/development company focused on creating value through the exploration and development of its British Columbia and Ontario mineral properties.
We seek Safe Harbor.
- Published in Crystal Lake Mining, News Home, Uncategorized
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
- Published in Uncategorized
Mobi724 Global Solutions Inc. (MOS:CSE) gets research coverage on WallStreetResearch.org
WallStreet Research Initiates Corporate Profile Update On Mobi724 Global Solutions, Inc. (MOS:CSE)
– Momentum Public Relations –
Research Coverage: Mobi724 Global Solutions
Mobi724GlobalSolutions.com (MOS:CSE), is a leader in the Fintech industry based in Montreal (Canada) and offers a unique and fully integrated suite of Payment & Digital Marketing solutions.
Wall Street Research initiated coverage of Mobi724 and wrote an initial ‘Corporate Profile’ to help US investors understand the opportunity. The major highlight for investors to take note of is that conservatively it was concluded that Mobi724’s valuation should be approximately $23million. Currently it is sitting between $5 and 6 million. Mobi724 is undervalued although it had strong revenue growth of 707{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} over past year and raised over $2.5million in capital over the last 9 months. The FinTech investing space is estimated to be worth over $20billion and is growing rapidly. With the additional visibility in the US and investors understanding the quickly rising valuation, Mobi724 represents exceptional upside potential.
View the The Wall Street Research:
Mobi724 Global Solutions, Inc. has recently registered with the SEC to be listed on the OTCQB – View Here
This initiative to list on the OTCQB was taken because of a visible increase in demand from the US investment market. As CEO Marcel Vienneau stated:
“Following interest from US investors, brokers and investment bankers, the company has decided to proceed with co listing application of the company on the OTCQB venture markets. We are optimistic that this initiative will give our company more visibility in a market where the Fintech sector is thriving. We want to leverage the additional visibility that this platform will give us in the small cap audience across the border. This is an important part of our 2017 strategy to get more visibility of our company to this target audience. We believe that this could bring more efficiencies to our stock trading as well. I am doing a multi city investor road show in the USA this week to kick off this initiative”
About WallStreetResearch.org
WallStreet Research™ (WSR) is a top ranked independent research firm with a history spanning over three decades. WSR provides the global investment community with independent analyst research reports, corporate profiles and newsletters of selected quality emerging growth companies.
With the #1 ranking on Google, Yahoo and Bing search engines, WallStreet Research effectively initiates coverage on emerging companies that offer remarkable gain potential. This has resulted in WSR achieving one of the best track records in the small cap investment market place. Our distribution is extensive and global, far outpacing our competitors, due to our long history, superior brand name, extensive proprietary database, our #1 search engine rankings, and strong capital position.
About Mobi724 Global Solutions
MOBI724 Global Solutions Inc. (CSE:MOS), a leader in the Fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of Payment & Digital Marketing solutions.
We are innovating in our market with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. We pioneered in adding intelligence to all types of transactions benefiting banks, retailers and cardholders. We succeed in leveraging all available user and purchasing data to increase transaction volumes and spend.
MOBI724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. Our easy-to-adapt gateway Switch is designed for easy integration with all payment protocols in our target markets.
Within the same solution suite we combined our Card Linked Offers solution, and provided financial institutions´ payment card portfolios and retailers the ability to add offers and/or coupons which can be redeemed directly at the Point of Sale, in a seamless user experience for all the parties in the eco-system.
MOBI724 Global Solutions unleashes the true potential of both payment and card-linked couponing/rewards transactions for both online and offline points of sale (POS).
The Corporation provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to ANY mobile device and allow its redemption at ANY point of sales.
Our credit and debit EMV payment solutions will allow banks to process end to end EMV transactions, focusing on authentication, approved security and quick merchant adoption which allows the users to process payments with a wide range of devices over a secure and seamless transaction.
MOBI724’s PCI and EMV cloud-based switch, with their device agnostic connectivity, simplifies deployment and integration, and introduces new payment and digital incentives solutions to the market enabling multi layered intelligent transactions therefore SMART TRANSACTIONS.
For more information on its products and on MOBI724 Global Solutions, visit www.mobi724globalsolutions.com.
Canada Strategic Metals (CJC.V) Starts Summer Exploration Program at Sakami Gold Project
Canada Strategic Metals (CJC.V) Starts Summer Exploration Program at Sakami Gold Project
– Momentum Public Relations –
Press Release: June 28, 2016
Canada Strategic Metals Inc. (“Canada Strategic Metals” or “the Company”) (TSX VENTURE:CJC)(FRANFURT:YXEN)(OTCBB:CJCFF) and Matamec Explorations Inc. (TSX VENTURE:MAT)(OTCQX:MHREF) are pleased to announce the beginning of the summer exploration program on Sakami Gold project.
Canada Strategic plans to conduct an important program of exploration between June 15th to August 15th, 2016. The program will includes magnetic-electromagnetic ground survey on La Pointe, JR West and Iles area, extensive prospection and stripping program on the Peninsula, JR and Iles area to test by sampling and tried to explain the anomalies identified by geochemistry and geophysics complete in 2014-2015 (see map below). Also, a ± 2000 meters drilling program is plan on the La Pointe area to extend the zone 25 to the North-west and to the south-east. (a map of localisation of plan drill hole is available at http://media3.marketwire.com/docs/strat_1_b.jpg).
The drilling program is aimed at increasing the size of the main gold zone (Zone 25) to the west-northwest, the South-east, as well as its extension at depth. Zone 25 is in the La Pointe sector of the Sakami property. Also, a lithological exploration hole is plan in the south portion of La Pointe. A surface map showing drill holes locations is available at http://media3.marketwire.com/docs/strat_2.jpg.
“We are very excited by this important exploration program that will include new drilling on the Sakami project during the month of July” said Jean-Sebastien Lavallée, President and Chief Executive Officer of Canada Strategic Metals. “The latest intersection of more than 45 meters containing significant gold grade was very encouraging and drilling in the extension of these zone can reveal significant results, including high grade as we can observe in Hole PT-15-87.”
Table of mineralized intersections from 2013-2015 drill holes
Hole # | From (m) | To (m) | Length* (m) | Au (g/t) |
PT-13-65 | 112.50 | 138.00 | 25.50 | 3.03 |
Including | 126.00 | 138.00 | 12.00 | 4.00 |
PT-13-67 | 126.90 | 154.85 | 27.95 | 3.78 |
Including | 132.25 | 154.85 | 22.60 | 4.01 |
Including | 138.00 | 145.00 | 7.00 | 7.21 |
PT-13-68 | 200.50 | 221.00 | 20.50 | 2.77 |
Including | 201.65 | 215.00 | 13.35 | 3.23 |
Including | 201.65 | 205.00 | 3.35 | 4.71 |
278.25 | 281.10 | 2.85 | 2.82 | |
294.00 | 297.00 | 3.00 | 1.70 | |
PT-13-71 | 49.10 | 51.65 | 2.55 | 2.06 |
102.00 | 121.50 | 19.50 | 2.97 | |
Including | 107.40 | 121.50 | 14.10 | 3.78 |
Including | 112.00 | 121.50 | 9.50 | 3.95 |
PT-13-72 | 112.50 | 130.40 | 17.90 | 2.24 |
Including | 112.50 | 119.00 | 6.50 | 3.65 |
PT-14-74 | 237.65 | 264.00 | 26.35 | 2.30 |
Including | 243.70 | 252.50 | 8.80 | 3.80 |
Including | 247.70 | 252.50 | 4.80 | 5.18 |
PT-14-79 | 188.00 | 236.20 | 48.20 | 2.51 |
Including | 188.00 | 200.00 | 12.00 | 6.93 |
Including | 190.00 | 196.00 | 6.00 | 11.35 |
Including | 202.50 | 207.00 | 4.50 | 1.33 |
Including | 226.50 | 234.00 | 7.50 | 3.06 |
PT-14-82 | 231.45 | 271,70 | 40.25 | 1.43 |
Including | 231.45 | 235.50 | 4.05 | 5.12 |
Including | 231.45 | 240.00 | 8.55 | 3.58 |
Including | 256.85 | 259.00 | 2.15 | 3.83 |
Including | 267.50 | 271.70 | 4.20 | 2.38 |
PT-14-83 | 240.00 | 295.50 | 55.50 | 1.06 |
Including | 240.00 | 252.00 | 12.00 | 3.54 |
PT-15-85 | 148.50 | 194.00 | 45.50 | 1.47 |
Including | 148.50 | 156.00 | 7.50 | 3.84 |
Including | 183.00 | 194.00 | 11.00 | 1.74 |
PT-15-87 | 219.40 | 229.00 | 9.60 | 6.86 |
Including | 220.50 | 227.00 | 6.50 | 9.9 |
* Core length; the Company estimates the true width of the mineralized zone at 70 to 90{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the core length.
The 2016 summer program is managed by Consul-Teck Exploration of Val-d’Or, Quebec who designed the drilling campaign, with the help of Guy Desharnais of SGS company.
Consul-Teck Exploration implemented QA/QC procedures to ensure best practices in sampling and analysis of the core samples. The drill core was logged and then split, with one-half sent for assay and the other retained in the core box as a witness sample. Duplicates, standards and blanks were inserted regularly into the sample stream.
The samples were delivered, in secure tagged bags, directly to the analytical facility for analysis; in this case ALS Minerals laboratory facility in Val-d’Or (Quebec). The samples are weighed and identified prior to sample preparation. All samples are analyzed by fire assay with AA finish on a 30g sample (0.005-10 ppm Au), with a gravimetric finish for assays over 10 ppm Au.
Jean-Sebastien Lavallée (OGQ #773), geologist, shareholder and President and Chief Executive Officer of the Company and a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.
Grant of options
The Company also announces that it has granted to Relations Publiques Paradox 450,000 stock options. The options will be exercisable for a period of two years, at a price of $0.10 per share. The Company will also extend the expiry date of 850,000 stock options issued in July 2014 for a period of two years.
These options will vest over a 12-month period at a rate of 25{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per quarter. The options are granted in accordance with the Policy 4.4 of the TSX Venture Exchange and the terms and conditions of the Company’s Stock Option Plan.
The above-mentioned are subject to the approval of the TSX Venture Exchange.
About Canada Strategic Metals
Canada Strategic Metals is an emerging company focused on the exploration and development of a number of projects covering over 22,584 hectares in Quebec. With broad management experience in green technology and junior resource exploration and development, Canada Strategic Metals is well positioned to aggressively advance this promising property portfolio for its shareholders.
For more information on the Company, please visit www.csmetals.ca.
- Published in Canadian Strategic CJC, Mining, News Home, Uncategorized